iCAD’s AI-powered solutions to Help Accelerate Breast Cancer Detection in New Collaboration with GE Healthcare
29 November 2023 - 12:00AM
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in
innovative cancer-detection solutions, today announced that key
artificial intelligence (AI) powered solutions from iCAD’s ProFound
Breast Health Suite are the first applications to be offered in GE
HealthCare’s new MyBreastAI Suite* offering.
As breast cancer becomes the most commonly diagnosed cancer
worldwide, iCAD’s AI solutions are integral to addressing critical
issues in breast imaging - such as access, burnout, variability,
equity, and cost. GE HealthCare’s MyBreastAI Suite, with iCAD's
three key AI-enabled solutions from iCAD, aims to streamline
workflow and help clinicians in accelerating breast cancer
detection and delivering more personalized and effective breast
care.
“iCAD has been collaborating with GE HealthCare for more than 20
years and this latest offering is a powerful affirmation of our
shared mission to advance breast health,” said Dana Brown,
President and CEO of iCAD, Inc. “Our ProFound AI DBT technology is
a cornerstone of AI-enabled solutions and is now offered as part of
GE HealthCare’s MyBreastAI Suite to seamlessly deploy AI to breast
imaging workflow to help enhance the detection and diagnosis of
breast cancer while optimizing workflow efficiency to ultimately,
help elevate patient care outcomes globally.”
MyBreastAI Suite provides an all-in-one platform that can
seamlessly deploy AI to breast imaging workflow. The first three AI
applications to be offered as part of the initial release include
the following solutions from iCAD:
- ProFound Detection, AI for Digital Breast Tomosynthesis (DBT):
A high-performing, deep-learning AI workflow solution that rapidly
evaluates 3D mammograms to detect malignant soft tissue densities
and calcifications with unrivaled accuracy, 2x enhanced clinical
performance compared to other AI platforms1. Providing Lesion
Scores and Case Scores, ProFound Detection aids in clinical
decision-making, workload prioritization, and could help reduce
burnout.
- SecondLook for 2D Mammography: Utilizes AI to identify
potential cancers in 2D mammography, marking suspicious areas
promptly and clearly.
- PowerLook Density Assessment: Automates breast density
evaluation, providing an objective, reproducible measure that is
crucial for personalized screening recommendations.
"Key AI-powered solutions from iCAD’s ProFound Breast Health
Suite are the first applications to be integrated with GE
HealthCare’s MyBreastAI Suite which is an exciting way to advance
our ongoing collaboration to continue deliver breast cancer
detection and diagnostic innovation," continued Brown.
Clinical studies have demonstrated that the use of iCAD’s
ProFound AI solutions can significantly improve reading sensitivity
and specificity, as well as reduce reading times, thus enhancing
clinical decision support and workflow efficiency for radiologists.
Specifically, ProFound AI offers clinically proven time-saving
benefits to radiologists, including a reduction of reading time by
52.7%, thereby halving the amount of time it takes radiologists to
read 3D mammography datasets. Additionally, ProFound AI for DBT
improved radiologist sensitivity by 8% and reduced unnecessary
patient recall rates by 7.2%.2
MyBreastAI Suite, featuring key iCAD AI-enhanced solutions, will
be available first in the United States and distributed, installed,
and supported by GE HealthCare as part of their Senographe Pristina
mammography portfolio.
This announcement coincides with GE HealthCare’s and iCAD’s
presence at the Radiological Society of North America (RSNA) annual
meeting in Chicago as it unveils new research evaluating its
ProFound AI in breast cancer risk detection and heart disease.
About iCAD, Inc. iCAD, Inc. (NASDAQ: ICAD)
is a global leader on a mission to create a world where
cancer can’t hide by providing clinically proven AI-powered
solutions that enable medical providers to accurately and
reliably detect cancer earlier and improve patient
outcomes. Headquartered in Nashua, N.H., iCAD’s
industry-leading ProFound Breast Health Suite provides
AI-powered mammography analysis for breast cancer detection,
density assessment and risk evaluation. The ProFound Breast
Health Suite is cleared by the U.S. Food & Drug
Administration (FDA) and has received CE mark and Health
Canada licensing. Used by thousands of providers serving
millions of patients, ProFound is available in over 50
countries. In the last five years alone, iCAD estimates reading
more than 40 million mammograms worldwide, with nearly 30% being
tomosynthesis. For more information,
visit www.icadmed.com.
Media Contacts:
iCAD Media inquiries:
pr@icadmed.com Investor Inquiries: ir@icadmed.com
1https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm.
Accessed 1-20-23. FDA 510K
submissions K182373 (iCAD), K201019 (Hologic)
and K193229 (ScreenPoint).2Conant, E. et al. (2019).
Improving Accuracy and Efficiency with Concurrent Use of Artificial
Intelligence for Digital Breast Tomosynthesis. Radiology:
Artificial Intelligence.
*MyBreastAI suite is a commercial offering that includes an AI
platform optimized for Mammography, ProFound Detection for DBT,
SecondLook for 2D Mammography and PowerLook® Density Assessment.
These three applications are provided by iCAD. MyBreastAI Suite is
compatible with the latest versions of iCAD, Inc. as of November
14, 2023.
Icad (NASDAQ:ICAD)
Historical Stock Chart
From Apr 2024 to May 2024
Icad (NASDAQ:ICAD)
Historical Stock Chart
From May 2023 to May 2024